These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39240836)

  • 1. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection following preoperative chemoradiotherapy.
    Yuge T; Murata Y; Noguchi D; Ito T; Hayasaki A; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Mizuno S
    PLoS One; 2024; 19(9):e0309834. PubMed ID: 39240836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Hoshi N; Hoshi S; Hirabayashi K; Ogata Y
    Pancreatology; 2017; 17(1):109-114. PubMed ID: 27840175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
    Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
    Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.
    Murata Y; Ogura T; Hayasaki A; Gyoten K; Ito T; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Sakurai H; Mizuno S
    PLoS One; 2022; 17(4):e0264573. PubMed ID: 35377885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma.
    Murata Y; Mizuno S; Kishiwada M; Uchida K; Noguchi D; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Kuriyama N; Sakurai H; Isaji S
    Pancreatology; 2021 Dec; 21(8):1482-1490. PubMed ID: 34452821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status.
    Sakoda T; Uemura K; Kondo N; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
    J Gastrointest Surg; 2021 Nov; 25(11):2871-2880. PubMed ID: 33768425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of peritoneal cytology in potentially resectable pancreatic cancer.
    Yamada S; Fujii T; Kanda M; Sugimoto H; Nomoto S; Takeda S; Nakao A; Kodera Y
    Br J Surg; 2013 Dec; 100(13):1791-6. PubMed ID: 24227366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
    Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection.
    Satoi S; Murakami Y; Motoi F; Uemura K; Kawai M; Kurata M; Sho M; Matsumoto I; Yanagimoto H; Yamamoto T; Mizuma M; Unno M; Hashimoto Y; Hirono S; Yamaue H; Honda G; Nagai M; Nakajima Y; Shinzeki M; Fukumoto T; Kwon AH
    J Gastrointest Surg; 2015 Jan; 19(1):6-14; discussion 14. PubMed ID: 25316482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative predictive factors for positive peritoneal cytology results in patients with pancreatic ductal adenocarcinomas: a retrospective study.
    Shimane G; Nakano Y; Kitago M; Yagi H; Abe Y; Hasegawa Y; Soga S; Okuda S; Ishii R; Kitagawa Y
    Int J Clin Oncol; 2024 Jul; 29(7):985-993. PubMed ID: 38598039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer.
    Tanemura M; Furukawa K; Mikamori M; Asaoka T; Yasuoka H; Marukawa D; Urata Y; Yamada D; Kobayashi S; Eguchi H
    Sci Rep; 2024 May; 14(1):10199. PubMed ID: 38702437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
    Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
    World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.
    Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
    Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy.
    Otsuka H; Uemura K; Kondo N; Sumiyoshi T; Okada K; Seo S; Murakami Y; Takahashi S
    Pancreatology; 2022 Jun; 22(5):583-589. PubMed ID: 35466060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer.
    Yoshioka R; Saiura A; Koga R; Arita J; Takemura N; Ono Y; Yamamoto J; Yamaguchi T
    World J Surg; 2012 Sep; 36(9):2187-91. PubMed ID: 22555286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
    Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
    Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma.
    Suenaga M; Fujii T; Yamada S; Hayashi M; Shinjo K; Takami H; Niwa Y; Sonohara F; Shimizu D; Kanda M; Kobayashi D; Tanaka C; Nakayama G; Koike M; Fujiwara M; Kondo Y; Kodera Y
    Ann Surg Oncol; 2021 Apr; 28(4):2277-2286. PubMed ID: 32875467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer Stratified by Cytologic Status.
    Ishida H; Ogura T; Takahashi A; Kitamura K; Miyamoto R; Matsudaira S; Tanabe M; Kanda H; Kawashima Y
    Cancer Diagn Progn; 2023; 3(3):338-346. PubMed ID: 37168974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.